Sensorion (ALSEN.PA) Aktie Kurs
Sensorion Kurs
De seneste 13 år voksede Sensorions omsætning med 164,9 % årligt og nåede 6,65 Mio. EUR. For Sensorion er nettoavance på -390,4 % ned i forhold til -381,7 % for et par år siden. Konsensus 12-måneders kursmål for Sensorion er 2,30 EUR, cirka under kursen med 73,9 %. Af 13 analytikere anbefaler 12 køb — den samlede vurdering er Køb.
Sensorion aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Sensorion aktie og aktieanalyse
Hyppigt stillede spørgsmål om Sensorion-aktien
Sensorion SA is a biopharmaceutical company specializing in the development of innovative therapies to address inner ear disorders. The company's business model revolves around the research, development, and commercialization of novel treatments for conditions such as vertigo and hearing loss. Sensorion SA aims to leverage its expertise in inner ear biology and drug development to create innovative therapies that can provide significant benefits to patients. With a focus on advancing its proprietary pipeline of drug candidates, Sensorion SA is dedicated to meeting the unmet medical needs in the field of inner ear disorders.
Sensorion SA is primarily active in the biotechnology industry.
The main competitors of Sensorion SA in the market are [competitor #1], [competitor #2], and [competitor #3]. These companies operate in the same industry as Sensorion SA and provide similar products or services. Despite facing competition, Sensorion SA has positioned itself as a key player in the market with its unique offerings. By continually innovating and delivering high-quality solutions, Sensorion SA maintains a competitive edge in the industry.
Sensorion SA is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for inner ear disorders. Founded in 2009, Sensorion has a strong focus on addressing unmet medical needs in the field of hearing loss and vestibular disorders. The company's research and development efforts primarily revolve around the identification, selection, and development of small molecules designed to protect, regenerate, and restore inner ear cells. With a deep commitment to improving the quality of life for patients suffering from hearing and balance disorders, Sensorion SA continues to pursue groundbreaking solutions to these debilitating conditions.
Sensorion SA, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed Phase 1 clinical trials for its novel therapy targeting inner ear disorders. It also received Orphan Drug Designation from the FDA for its product candidate, confirming its potential to address unmet medical needs. Furthermore, Sensorion SA successfully initiated Phase 2 clinical trials, demonstrating promising results in patients with sudden sensorineural hearing loss. The company's collaborations with renowned academic institutions highlight its commitment to advancing research in the field. Overall, Sensorion SA's achievements reflect its dedication to revolutionizing treatments for inner ear disorders, positioning it as a key player in the industry.
Sensorion SA is primarily present in several countries and regions globally. These include the United States, Europe, and Asia. The company has established a strong presence in the United States, where it conducts significant research and development activities. In Europe, Sensorion SA has partnerships and collaborations with various academic institutions and pharmaceutical companies. Additionally, the company has expanded its reach in Asia through strategic alliances and distribution agreements. With its global presence, Sensorion SA aims to address the unmet medical needs of patients suffering from inner ear disorders and provide innovative solutions in the field of hearing and balance disorders.
Sensorion SA is a leading biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. The company's values revolve around scientific excellence, patient-centered approach, and commitment to improving the lives of individuals suffering from vestibular and hearing impairments. Sensorion SA aims to provide effective and safe treatment solutions while prioritizing the needs and well-being of patients. With a strong corporate philosophy grounded in research and development, Sensorion SA strives to address the unmet medical needs in the field of auditory disorders, aiming to make a meaningful impact on the lives of individuals affected by these conditions.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 2,42 EUR for Sensorion-aktien (median: 2,30 EUR), svarende til -72,5 % i forhold til seneste kurs. Konsensus bygger på 13 analytikervurderinger.
14 analytikere vurderer i øjeblikket Sensorion-aktien: 13 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Sensorion genererer omsætning på 4,55 Mio. EUR og indtjening pr. aktie på -169,83 EUR.
Sensorion-aktien (ALSEN.PA) er noteret på 5 børser, herunder: Frankfurt (RFM.F), München (RFM.MU), Düsseldorf (RFM.DU), Paris (ALSEN.PA).
Sensorion SA is a French biotechnology company specializing in the development of novel therapies for the treatment of inner ear disorders and hearing loss. The company focuses on researching and developing drugs tailored to the specific needs of patients. Sensorion aims to create innovative products and therapies in the field of otolaryngology to meet the needs of patients.
forventet-omsætningen for Sensorion er 4,55 Mio. EUR. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Sensorion er -1,02 Mrd. EUR. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Sensorion er i øjeblikket -0,05. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Sensorion-aktien.
Pris-til-salgs-forholdet (P/S) for Sensorion er i øjeblikket 11,63. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Sensorion-aktien.
AlleAktien-kvalitetsscore for Sensorion er 2/10.
ISIN for Sensorion er FR0012596468. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Sensorion er A14SVV. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Sensorion er ALSEN.PA. Tickersymbolet bruges til at handle Sensorion-aktier på børsen.
Sensorion aktie
Sensorion Peer Group
Sensorion Ticker
Sensorion FIGI
Alle fundamentale data om Sensorion i deep dive
Vores aktieanalyse af Sensorion-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Sensorion. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: